The HSE-Medicines Management Programme (MMP) has completed a review of the medicinal products containing teriparatide that are available on the High-Tech Arrangement and is now recommending a number of best-value medicines (BVMs) for teriparatide.
The MMP recommends Movymia® and Sondelbay® as the BVMs for teriparatide on the HighTech Arrangement. An evaluation report entitled Best-Value Medicines: Teriparatide on the HighTech Arrangement is available on the HSE-MMP website.
From 1 March 2023, reimbursement of teriparatide on the High-Tech Arrangement will only be supported for the identified BVMs (i.e. Movymia® and Sondelbay®) in adult patients commencing such therapy. When issuing a repeat prescription for a patient who is established on a medicinal product containing teriparatide, prescribers are advised that the patient should be considered for switching to Movymia® or Sondelbay®.
Further information and a range of resources to support prescribing of the identified BVMs (i.e. Movymia® and Sondelbay®) are available on the HSE-MMP website.
